GO
Loading...

CNBC Explains: Immuno-what?

The year's biggest event in cancer research, ASCO, or the American Society of Clinical Oncology meeting, kicks off Friday in Chicago, and is bound to send stocks flying early next week on data being presented.

Analysts say the key theme will be immunotherapies, drugs that harness the immune system to fight cancer. Companies including Bristol-Myers Squibb, Merck, AstraZeneca and Novartis, as well as smaller biotechs like Incyte, Juno Therapeutics and Kite Pharma, are all working in the space.

Read MoreThis year, at ASCO, all eyes are on pharma

For Bristol-Myers alone, BMO analyst Alex Arfaei estimates the drugs could bring in $12.9 billion in peak annual revenue.

ASCO will provide an updated glimpse of the promise of these medicines. So how do they work? Check out the video above.

Read MoreThese stocks are moving on cancer research news

—By CNBC's Meg Tirrell.

Contact CNBC Explains

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Latest Special Reports

  • Financial advisors stress that now is the time for investors to get serious about year-end financial planning checkup.

  • Is an active twist on passive investing the right portfolio move? An inside look at the rise of ETF strategists.

  • The nexus of technology -- cloud, social, mobile and data -- are transforming user behaviors and creating new businesses.

Central Banking Explained

Corporate Accounting Explained